Background: Acute pancreatitis is one of the commonest diseases. While some use octreotide infusion, some rely only on fluid therapy and symptomatic treatment. Ongoing research has commented about omega (ω) 3 fatty acid (FA) infusions being the future of acute pancreatitis treatment as it is cheap and has lesser side effects.Methods: This prospective comparative study was done in patients with acute pancreatitis. Patients were divided into two groups, with group A receiving ω-3 FA single-dose infusion of 60 ml/hour over 4-5 hours and the other group B were subjected to injection of octreotide 100 mcg IV 8th hourly for 5 days with IV fluids. The groups were compared based on improvement in biochemical markers, BISAP score and hospital stay.Results: 132 patients were divided into 2 groups, on day 3 serum amylase levels in the ω-3 FA group were 268.54±65.84, and the octreotide group was 299.18±94.31 (p value=0.032). Day 3 serum lipase levels in the ω-3 FA group were 137.07±62.19, and the octreotide group was 172.07±72.46 (p value=0.002). Day 3 BISAP score in the ω-3 FA group was 1.21±0.41, and the octreotide group was 1.39±0.49 (p value=0.023). The duration of hospital stay in the ω-3 FA group was 8.03±1.09 days and in the octreotide group was 11.83±1.04 days (p<0.0001).Conclusions: Patients receiving ω-3 FA reported lower amylase-lipase levels along with a lower BISAP score. Hence looking for a cheaper and safer alternative, ω-3 FA infusion could reduce the problem on the patient and hospitalization concomitant expenses.
BACKGROUND:In India, locally advanced breast cancer (LABC) is responsible for 30 - 35% of all breast cancer cases. The purpose of preoperative chemotherapy is that it is capable of shrinking large primary tumors rendering many inoperable patients operable METHODS: 2 2 The doses of the drugs used were Cyclophosphamide - 600 mg/m IV infusion, Adriamycin - 50 mg/m IV infusion 2 and 5 uorouracil (FU) - 600 mg/m IV infusion. Clinical response was noted after 3 weeks of third cycle of NACT which was assessed according to RECIST criteria RESULTS: 78.1% of our patients responded to NACT (cCR + cPR) with pCR in 17.2% of patients. percentage of complete response was higher for patients in stage IIIA than for the patient in stage IIIB CONCLUSION: neo-adjuvant chemotherapy integrated into a multi-modality program is the standard management in patients with locally advanced breast carcinoma. The patients with pathological complete response and patients without axillary lymph node were associated with improved outcome after neo adjuvant chemo therapy
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.